Medical Student University of Texas Medical Branch EDINBURG, Texas, United States
Disclosure(s):
Charles T. Park: No financial relationships to disclose
Background: Interleukin 6 is a strong biomarker for mortality in patients with cardiogenic shock. Elevated IL-6 has been linked to fibromyalgia where treatment primarily focuses on symptom management through pregabalin. This study aims to explore whether treatments commonly used for fibromyalgia could offer a protective benefit for cardiogenic shock, through IL-6.
Methods: This investigation utilized the TriNetX platform (www.trinetx.com), a comprehensive global research network with confidential patient data to compare outcomes of patients with various cardiovascular diseases known to predispose them to cardiogenic shock and the presence/absence of fibromyalgia. ICD-10 codes used include: I50 heart failure; M79.7 fibromyalgia; I21 acute myocardial infarction; I20.0 unstable angina. Patients were balanced according to common demographic factors, including age, sex, and ethnicity. P-value of < 0.05 is deemed significant for this study.
Outcome: Patients with fibromyalgia demonstrated a significantly lower risk of developing cardiogenic shock when compared to their counterparts without fibromyalgia. Interestingly, the largest difference among the cohorts is found in patients with heart failure, as patients with heart failure and those without fibromyalgia had a 0.498% increased risk of developing cardiogenic shock.
Conclusion: Our data indicates a reduction in risk for those with predisposing risk factors being treated for fibromyalgia to develop cardiogenic shock. Pregabalin, a treatment option for fibromyalgia, has the potential to reduce IL-6 and is linked to predicting mortality in cardiogenic shock, a potential preventative treatment option for CS.
